Extraintestinal manifestations (EIMs) represent symptoms outside the gastrointestinal tract and frequently occur among patients with ulcerative colitis (UC). The aim of the current study was to estimate the prevalence of EIMs in UC patients initiating biologic therapy and how they influence real-world treatment patterns and outcomes in the United States.